Pembrolizumab NCT07302347 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 18 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 1/2

Clinical phase

Recruiting

Recruitment status

20

Planned enrollment

2029-03-30

Primary-completion proxy

Executive view

NCT07302347 evaluates Pembrolizumab in Hodgkin's Lymphoma. The disclosed sponsor is Merck Sharp & Dohme LLC, the design is Interventional, and the geographic footprint is Japan. The first listed primary endpoint is Arm 1: Number of Participants Who Experience an Adverse Event (AE), assessed over Up to approximately 28 months.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07302347 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Hodgkin's Lymphoma landscape. Drug & Asset MCP drug_fetch was queried for Pembrolizumab, while Company & Deal Intelligence MCP organization_fetch was queried for Merck Sharp & Dohme LLC.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT07302347	Pembrolizumab	Phase 1/2 / Recruiting	Merck Sharp & Dohme LLC	Japan	Arm 1: Number of Participants Who Experience an Adverse Event (AE) Up to approximately 28 months	2029-03-30
NCT07504796	Ipilimumab	Phase 2 / Recruiting	NYU Langone Health	United States	Progression Free Survival rate in patients randomized in Cohort B Month 6	2029-05-01
NCT07501117	Ipilimumab	Phase 1 / Recruiting	Herlev Hospital	Denmark	Number of patients experiencing CTCAE grade ≥ 3 AEs and the occurrence of any treatment related adverse event (AEs) Until 6 months post treatment	2029-06-01
NCT07476326	Nivolumab	Phase 1 / Not yet recruiting	Biocon Biologics Uk Plc	Romania, Ukraine, Turkey, Brazil, South Africa, Moldova, United States, Serbia, Chile, Spain	Area Under the Concentration-Time Curve from Time 0 (Day 1) To Day 29 After the First Dose (AUC0-28days) of Bmab 1700 a… Week 0 through Week 4	2027-08-16
NCT07475572	Pembrolizumab biosimilar(Alvotech)	Phase 1 / Recruiting	Alvotech Swiss AG	Ukraine	To demonstrate PK similarity of AVT32-DRL_PB versus Keytruda (pembrolizumab) Cycle 1 (each cycle is 21 days)	2027-10-01

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT07302347 is a Phase 1/2, recruiting study with 20 planned participants. Allocation is Non-Randomized, masking is Single, and the intervention model is Parallel Assignment.

The primary endpoint is “Arm 1: Number of Participants Who Experience an Adverse Event (AE)” over “Up to approximately 28 months.” The retrieved endpoint description is: An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study intervention. The number of participants with solid tumors or lymphomas who experience an AE will be reported..

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 20 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

5 recent result records were selected as contextual evidence for Hodgkin's Lymphoma. These records do not establish direct evidence for NCT07302347 unless the registration number matches.

A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma

Phase 2; n=30; AE(Grade 3 and higher) = 50.0 % Source: https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/41732954/

A Phase II Study to Evaluate the Safety and Efficacy of Rigosertib (ON 01910) Plus Pembrolizumab in Patients With Metastatic Melanoma Refractory to Immune Checkpoint Blockade

Phase 2; n=7; ORR = 0 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05764395

A Phase 2 Study of Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Patients With Percutaneously Accessible Lesions With Advanced Melanoma Refractory to PD-1…

Phase 2; n=23; CR = 0 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT04796194

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

Pembrolizumab is indexed as Monoclonal antibody with PD-1 biology and a global stage of Approved. The asset profile lists Merck & Co., Inc. as an originator or developer.

Merck Sharp & Dohme LLC is indexed in United States with the website http://www.merck.com.libproxy1.nus.edu.sg Operates as a research-intensive biopharmaceutical company that develops medicines and vaccines for cardiometabolic & respiratory diseases The record lists 144 development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Pembrolizumab is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT07302347
Protocol source: https://clinicaltrials.gov/study/NCT07302347
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 18 September 2026.

Pembrolizumab in Hodgkin's Lymphoma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Arm 1: Number of Participants Who Experience an Adverse Event (AE) and 2029-03-30 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP